Delaware
|
001-37568
|
26-4231384
|
(State or Other Jurisdiction of Incorporation or Organization)
|
(Commission File Number)
|
(I.R.S. Employer Identification No.)
|
300 Connell Drive, Suite 4000
Berkeley Heights, NJ
|
07922
|
|
(Address of Principal Executive Offices)
|
(Zip Code)
|
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Title of each class
|
Trading symbol(s)
|
Name of each exchange on which registered
|
Common Stock, par value $0.00033 per share
|
PDSB
|
Nasdaq Capital Market
|
Item 5.08. |
Shareholder Director Nominations.
|
Dated: August 5, 2019
|
PDS Biotechnology Corporation
|
|
By:
|
/s/ Frank Bedu-Addo, Ph.D.
|
|
Name: Frank Bedu-Addo, Ph.D.
|
||
Title: President and Chief Executive Officer
|